In particular, therapeutic blockade of CCL2-CCR2 interaction by using CCL2 neutralizing antibodies or CCR2 antagonist has demonstrated promising antitumor efficacies in several preclinical cancer models (42–44). This evidence concerns the gene CCR2 and cancer.